Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

OSMOPREP

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

Standard Dose
0.398GM;1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview OSMOPREP is listed in Drugs@FDA under application 021892 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE Form and strength TABLET;ORAL - 0.398GM;1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SALIX PHARMS Submission history Latest submission status date: 2018-11-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview OSMOPREP is listed in Drugs@FDA under application 021892 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE Form and strength TABLET;ORAL - 0.398GM;1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SALIX PHARMS Submission history Latest submission status date: 2018-11-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.